T. Rowe Price Associates’s Solid Biosciences SLDB Stock Holding History

T. Rowe Price Associates’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$646K	Buy	64,637 +24,290	+60%	+$184K	﹤0.01%	2502
2026 Q1	$291K	Buy	40,347 +5,260	+15%	+$33.8K	﹤0.01%	2694
2025 Q4	$198K	Hold	35,087	–	–	﹤0.01%	2814
2025 Q3	$217K	Buy	35,087 +2,010	+6%	+$11.8K	﹤0.01%	2761
2025 Q2	$162K	Buy	33,077 +21,519	+186%	+$76.1K	﹤0.01%	2783
2025 Q1	$43K	Buy	+11,558	New	+$49.5K	﹤0.01%	2948
2021 Q4	–	Sell	-272,557	Closed	-$9.77M	–	3034
2021 Q3	$9.77M	Sell	272,557 -655	-0.2%	-$27.8K	﹤0.01%	1421
2021 Q2	$15M	Sell	273,212 -7,388	-3%	-$488K	﹤0.01%	1364
2021 Q1	$23.3M	Buy	+280,600	New	+$31M	﹤0.01%	1243

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's SLDB Position: Q2 2026 in Review

T. Rowe Price Associates increased its Solid Biosciences (SLDB) stake by 60% in Q2 2026, buying an estimated $184K and bringing the position to 64,637 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #2502.

T. Rowe Price Associates first reported a position in SLDB in Q1 2021 and has held it in 9 quarters since. The position peaked at $23.3M in Q1 2021. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

T. Rowe Price Associates held 64,637 shares of Solid Biosciences worth $646K as of Q2 2026.
T. Rowe Price Associates bought 24,290 Solid Biosciences shares in Q2 2026, an estimated $184K.
Solid Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2502 holding.
T. Rowe Price Associates first reported a position in Solid Biosciences in Q1 2021 and has held it in 9 quarters since.
T. Rowe Price Associates's Solid Biosciences position peaked at $23.3M in Q1 2021.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.